Journal
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume 53, Issue 2, Pages 168-173Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jjco/hyac154
Keywords
gastric cancer; preoperative chemotherapy
Categories
Ask authors/readers for more resources
This study aims to investigate the difference in overall survival between preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy and D2 gastrectomy with postoperative chemotherapy only in patients with clinical T3-4N1-3 M0 locally advanced gastric cancer.
In Japan, postoperative chemotherapy is a standard care for stage II/III gastric cancer after curative resection with D2 lymph node dissection, and the clinical outcomes of patients with stage Ill gastric cancer are unsatisfactory. A combination of oral S-1 and oxaliplatin, that is the standard chemotherapy regimen for unresectable advanced/recurrent gastric cancer associated with a high response rate, was considered the most promising preoperative chemotherapy regimen. This randomized phase Ill trial was started in September 2016 to confirm the superiority of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative chemotherapy compared with D2 gastrectomy with postoperative chemotherapy for patients with clinical T3-4N1-3 M0 locally advanced gastric cancer in terms of overall survival. A total of 470 patients will be enrolled from 63 hospitals in Japan for 8.5 years. This trial has been registered in the Japan Registry of Clinical Trials as jRCTs031180350 [https://jrct.niph.go.jp/latest-detail/jRCTs031180350].
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available